GDC-0077

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name: GDC-0077
DrugBank Accession Number: DB15275
Background: GDC-0077 is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).
Type: Small Molecule
Groups: Investigational
Structure: 3D
MOL SDF 3D-SDF PDB SMILES InChI

Similar Structures
Structure for GDC-0077 (DB15275)
Synonyms: Not Available

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

UNII: L4C1UY2NYH
CAS number: 2060571-02-8
InChI Key: SGEUNORSOZVTOL-CABZTGNLSA-N
InChI: InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1
IUPAC Name: (2S)-2-({4-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-9-oxa-3,6-diazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),2,4,10,12-pentaen-12-yl}amino)propanamide
SMILES: C[C@H](NC1=CC=C2C3=NC(=CN3CCOC2=C1)N1[C@@H](COC1=O)C(F)F)C(N)=O

General References

Not Available

External Links

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Recruiting	Treatment	Advanced Unresectable or Metastatic Solid Malignancy	1
2	Recruiting	Treatment	Breast Cancer / Triple Negative Breast Cancer	1
2	Recruiting	Treatment	Solid Tumors	1
2, 3	Recruiting	Treatment	Breast Cancer	1
1	Recruiting	Treatment	Breast Cancer / Solid Tumors	1
1, 2	Recruiting	Treatment	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	1

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Predicted ADMET Features

Not Available

Drug created at May 20, 2019 15:06 / Updated at June 12, 2020 16:53